Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Addex Therapeutics Ltd
  6. News
  7. Summary
    ADXN   CH0029850754

ADDEX THERAPEUTICS LTD

(ADXN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Addex Therapeutics : Q1 Loss Shrinks on Positive Finance Income

05/05/2021 | 01:22am EDT


© MT Newswires 2021
All news about ADDEX THERAPEUTICS LTD
06/07ADDEX THERAPEUTICS  : Commences Enrollment in Phase 2 Trial of Epilepsy Drug
MT
06/07ADDEX THERAPEUTICS  : First patients enrolled into multi-center U.S. study (Form..
PU
06/07ADDEX THERAPEUTICS  : Enrolls First Patient in Mid-Stage Study of Epilepsy Drug
MT
06/07PRESS RELEASE : Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy
DJ
06/07Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy
GL
05/24PRESS RELEASE : Addex to Participate at the Benchmark Company Healthcare House C..
DJ
05/24ADDEX THERAPEUTICS  : to Participate at the Benchmark Company Healthcare House C..
AQ
05/24Addex to Participate at the Benchmark Company Healthcare House Call Conferenc..
GL
05/17PRESS RELEASE : Addex's Dipraglurant Restores Synaptic Plasticity in Models of D..
DJ
05/17Addex's Dipraglurant Restores Synaptic Plasticity in Models of Dystonia
DJ
More news
Financials
Sales 2021 1,61 M 1,79 M 1,79 M
Net income 2021 -15,1 M -16,8 M -16,8 M
Net Debt 2021 5,28 M 5,88 M 5,88 M
P/E ratio 2021 -3,72x
Yield 2021 -
Capitalization 69,7 M 77,6 M 77,6 M
EV / Sales 2021 46,6x
EV / Sales 2022 76,6x
Nbr of Employees 27
Free-Float 77,4%
Chart ADDEX THERAPEUTICS LTD
Duration : Period :
Addex Therapeutics Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADDEX THERAPEUTICS LTD
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 1,08 CHF
Last Close Price 1,60 CHF
Spread / Highest target -32,5%
Spread / Average Target -32,5%
Spread / Lowest Target -32,5%
EPS Revisions
Managers and Directors
NameTitle
Timothy Dyer Chief Executive Officer & Director
Lénaic Teyssédou Head-Finance
Vincent M. Lawton Chairman
Roger G. Mills Director & Chief Medical Officer
Raymond George Hill Director
Sector and Competitors
1st jan.Capitalization (M$)
ADDEX THERAPEUTICS LTD-19.60%78
MODERNA, INC.109.49%87 874
LONZA GROUP AG16.32%54 656
IQVIA HOLDINGS INC.35.87%46 658
CELLTRION, INC.-26.04%32 458
SEAGEN INC.-10.60%28 416